The Gastric Cancer Center currently offers the following subspecialties:

1. Gastric Cancer Surgery
This subspecialty is characterized by precision medicine and multidisciplinary comprehensive treatment, focusing on standardized minimally invasive treatment for gastric cancer, neoadjuvant therapy, precision diagnosis and treatment, management of adenocarcinoma of the esophagogastric junction, and the development of intelligent surgical platforms. It is committed to providing scientifically standardized diagnostic and treatment plans for gastric cancer patients to improve long-term outcomes. The team currently includes 18 senior professional title holders, 9 doctoral supervisors, and 8 master's supervisors. Among them are 1 principal investigator of a National 863 Program project, 1 Vice President of the Endoscopic Physicians Branch of the Chinese Medical Doctor Association, 2 nationally recognized talents, 1 recipient of the Ministry of Education's New Century Excellent Talents Support Program, 1 Chief Expert of Health in Sichuan Province, and 8 Academic and Technical Leaders of Sichuan Province. The team has achieved significant research outcomes in areas such as capturing gastric cancer stem cells (Cell Res), uncovering genetic characteristics and drug resistance mechanisms of gastric signet ring cell carcinoma (Nat Commun), and CAR-T therapy for gastric cancer (Science Advance). The team has led the development of three national consensus statements on gastric cancer and established the Chinese Laparoscopic Surgical Technique Assessment and Evaluation Standard System (CLSTA), leading the advancement of the discipline.

2. Gastric Cancer Medical Oncology
As a specialized disease center, the Gastric Cancer Center manages one of the highest volumes of gastric cancer cases in China. The Medical Oncology subspecialty focuses on precise clinical staging of gastric cancer, stratified perioperative treatment for locally advanced gastric cancer, and individualized treatment strategies for advanced gastric cancer. The integration of surgical and medical oncology within the center provides an excellent platform for exploring precision perioperative treatment models. Currently, the center leads nationally in laparoscopic exploration rates, neoadjuvant therapy rates, and clinical research on neoadjuvant therapy for locally advanced gastric cancer. For advanced gastric cancer, the center delivers precision individualized treatment based on molecular biomarkers and sites of metastasis. Peritoneal metastasis, one of the most common and prognostically unfavorable metastatic sites in gastric cancer, has a low response rate to conventional chemotherapy and immunotherapy. For advanced gastric cancer patients with peritoneal metastasis, the center offers hyperthermic intraperitoneal chemotherapy combined with systemic chemotherapy and immunotherapy, significantly improving patient outcomes. In addition, the center conducts multiple clinical trials for novel drugs and investigator-initiated trials for advanced gastric cancer. The center provides "one-stop" multidisciplinary diagnosis, treatment, and comprehensive management for every patient, achieving high overall patient satisfaction.

3. Gastric Cancer Nutrition
As the chair unit of the Parenteral and Enteral Nutrition Branch of the Sichuan Medical Association and its Youth Committee, this subspecialty focuses on perioperative nutritional therapy for gastric cancer patients. It is nationally renowned for clinical nutrition techniques including parenteral nutrition, enteral nutrition, and oral nutritional supplements (ONS). The team provides comprehensive nutritional support throughout the entire course of gastric cancer treatment and standardized nutritional management during the neoadjuvant period, achieving high patient satisfaction.

4. Gastrointestinal Stromal Tumors (GIST)
Led by Professor Zhang Bo, the GIST subspecialty is dedicated to providing individualized comprehensive diagnosis and treatment for patients with gastrointestinal stromal tumors (GIST). It has established a multidisciplinary team (MDT) and implements and promotes standardized, precise, and individualized targeted therapy for GIST. The team possesses advanced treatment concepts and extensive clinical experience in standardized surgical treatment, adjuvant/neoadjuvant drug therapy, and comprehensive management of patients with advanced GIST. The subspecialty provides patients with access to clinical trials of novel anticancer drugs and has participated in multiple international and domestic clinical studies on new GIST drugs. Core members of the subspecialty hold key positions in major national academic organizations, including Deputy Leader of the GIST Diagnosis and Treatment Expert Working Group of the Surgeons Branch of the Chinese Medical Doctor Association, Vice Chair of the GIST Expert Committee of the Chinese Society of Clinical Oncology (CSCO), Standing Committee Member of the GIST Expert Committee of the Chinese Anti-Cancer Association, Chair-Elect of the GIST Expert Committee of the Sichuan Anti-Cancer Association, and Leader of the GIST Study Group of the Surgeons Branch of the Sichuan Medical Doctor Association, among others. Core members have also served as principal writers in the development of multiple Asian and Chinese guidelines and consensus statements on GIST diagnosis and treatment, with their research findings cited by international guidelines such as the NCCN guidelines.

The subspecialty has received support from multiple research funding sources, including three projects from the National Natural Science Foundation of China, six projects from the Sichuan Provincial Science and Technology Department, projects from the China Postdoctoral Science Foundation, international and domestic multicenter clinical research projects, and the hospital's 135 Project. It has published over 30 SCI-indexed papers.

In addition, our hospital manages approximately 300–400 newly diagnosed GIST cases annually. Based on these cases, the GIST subspecialty has established a comprehensive GIST database that includes clinical and pathological information, genetic testing data, imaging data, laboratory test indicators, and follow-up information. Currently, the database contains over 3,000 GIST cases. The subspecialty conducts multiple clinical studies, providing patients with access to clinical trials of novel anticancer drugs. Regular patient education sessions are held to explore topics such as disease etiology, pathology, and treatment advances, promoting disease awareness and standardized treatment pathways. These efforts help patients and their families develop a more systematic, in-depth, and intuitive understanding of GIST, laying a solid foundation for promoting standardized treatment, improving long-term treatment adherence, and enhancing follow-up compliance.